Bacteria Clinical Development Containment 
The Pharma Data
JANUARY 4, 2021
In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. For more information, please visit www.polyphor.com.
Pfizer
FEBRUARY 16, 2023
While VLA15 is still under investigation, to date the companies have been encouraged by the data from the Phase 2 clinical studies, which demonstrated strong immunogenicity and acceptable safety and tolerability profiles. 2-4 About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JULY 18, 2021
Pneumococcal disease is an infection caused by bacteria called Streptococcus pneumoniae, or pneumococcus. Different strains of this bacteria are called serotypes. Invasive pneumococcal disease (IPD) occurs when the bacteria infect parts of the body that are usually free from germs. pneumoniae serotypes contained in the vaccine.
Delveinsight
JULY 27, 2021
This globalized COVID-19 vaccine supply chain and manufacturing network, incorporates 3 continents and will contain around 20 manufacturing facilities. As suggested by analysts, the most rapid, cost-effective and easiest way of vaccine development is regional partnership with prominent vaccines developers.
The Pharma Data
DECEMBER 13, 2020
In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. For more information, please visit www.polyphor.com.
The Pharma Data
DECEMBER 21, 2020
22, 2020 (GLOBE NEWSWIRE) — Polyphor AG (SIX: POLN) today announced that the UK Medicines and Healthcare products regulatory agency (MHRA) has granted a CTA (Clinical Trial Authorization) to start the first-in-human Phase I study of its novel class antibiotic murepavadin, delivered via the oral inhalation route.
The Pharma Data
DECEMBER 13, 2020
The Nature Communications publication titled, “Immunotherapy with an engineered bacteria by targeting the STING pathway for anti-tumor immunity,” details the engineering and characterization of SYNB1891 (Leventhal, D.S., SYNB1891 is being evaluated in a Phase 1 clinical trial. Sokolovska, A.,
Expert insights. Personalized for you.
52 
Let's personalize your content